Research on the drug treatment of schizophrenia: A critical appraisal and implications for social work education

Journal of Social Work Education

Volumn 38, Issue 2, 2002, Pages 217-239

  Cohen, David ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035994859     PISSN: 10437797     EISSN: 21635811     Source Type: Journal    
DOI: 10.1080/10437797.2002.10779094     Document Type: Article

References (146)

1. Abraham, J. (1995). Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL Press.
2. Agency for Health Care Policy and Research. (1999). Treatment of Attention-Deficit/Hyper-activity Disorder. (AHCPR Publication No. 99-E017). Rockville, MD: Author.
3. Ahmed, I., Soares, K., Seifas, R., & Adams, C. E. (1998). Randomized controlled trials in Archives of General Psychiatry (1959-1995): A prevalence study. Archives of General Psychiatry, 55, 754-755.
4. Ahmed, S., Chengappa, K. N., Naidu, V. R., Baker, R. W., Parepally, H., & Schooler, N. R. (1999). Clozapine withdrawal-emergent dystonias and dyskinesias: A case series. Journal of Clinical Psychiatry, 59, 472-477.
5. Al-Waneen, R. (2000). Neuroleptic malignant syndrome associated with quetiapine. Canadian Journal of Psychiatry, 45, 764-765.
6. Ananth, J., & Kenan, J. (1999). Tardive dyskinesia associated with olanzapine monotherapy. Journal of Clinical Psychiatry, 60, 870.
7. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy & Psychosomatics, 68(1), 3-14.
8. Austrian, S. G. (2000). Mental disorders, medications, and clinical social work. New York: Columbia University Press.
9. Awad, A. G., & Hogan, T. P. (1994). Subjective response to neuroleptics and the quality of life: Implications for treatment outcome. Acta Psychiatrica Scandinavica, 89(Suppl. 380), 27-32.
10. Baldessarini, R. J., Kando, J. C., & Centorrino, F. (1995). Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay. American Journal of Psychiatry, 141, 748-752.
11. Baldessarini, R. J., & Viguera, A. C. (1995). Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52, 189-192.
12. Barnes, T. R. E, Milavic, G., Curson, D. A., & Platt, S. D. (1983). Use of the Social Behavior Assessment Schedule (SB AS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: Pimozide versus fluphenazine. Social Psychiatry, 18, 193-199.
13. Bentley, K. J. (1998). Psychopharmacological treatment of schizophrenia: What social workers need to know. Research on Social Work Practice, 8, 384-405.
14. Bentley, K. J., & Walsh, J. F. (2001). The social worker and psychotropic medication: Toward effective collaboration with mental health clients, families, and providers (2nd ed.). Belmont, CA: Brooks/Cole.
15. Berecz, R., Gaub, T., Kellerman, M., de la Rubia, A., Llerena, A., & Degrell, I. (2000). Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient. Pharmacopsychiatry, 33(1), 42-44.
16. Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. New England Journal of Medicine, 342, 1539-1544.
17. Boseley, S. (2002, February 7). Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian [Electronic version]. Retrieved February 8, 2002, from http://www.guardian.co.uk/Archive/Article/0, 4273,4351264,00.html.
18. Breggin, P. R. (1991). Toxic psychiatry. New York: St. Martin’s Press.
19. Breggin, P. R. (2000). A critical analysis of the NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder (the MTA study). Ethical Human Sciences and Services, 2(1), 63-72.
20. Breggin, P. R., & Cohen, D. (2000). Your drug may be your problem: How and why to stop taking psychiatric medication. Cambridge, MA: Perseus Books.
21. Brown, P., & Funk, S. C. (1986). Tardive dyskinesia: Professional barriers to the recognition of an iatrogenic disease. Journal of Health and Social Behavior, 27, 116-132.
22. Canales, P. L., Olsen, J., Miller, A. L., & Crismon, M. L. (1999). Role of antipsychotic polypharmacy in the treatment of schizophrenia.CNS Drugs, 12, 179-188.
23. Carpenter, W. T., Buchanan, R. W., Kirkpatrick, B., & Breier, A. F. (1999). Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry, 156, 299-303.
24. Chalmers, I. (1990). Underreporting research is scientific misconduct. JAMA, 263, 1405-1408.
25. Choudhry, N. K., Stelfox, H. T., & Detsky, A. S. (2002). Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA, 287, 612-617.
26. Cohen, B. M., Herschel, M., Miller, E., Mayberg, H., & Baldessarini, R. J. (1980). Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology, 19, 663-668.
27. Cohen, D. (1994). Neuroleptic drug treatment of schizophrenia: The state of the confusion. Journal of Mind and Behavior, 15, 139-156.
28. Cohen, D. (1997a). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher & R. G. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 173-228). New York: Wiley.
29. Cohen, D. (1997b). Psychiatrogenics: Introducing chlorpromazine in psychiatry. Review of Existential Psychology and Psychiatry, 23, 206-233.
30. Cohen, D. (2001). Medication-free minors with schizophrenia. American Journal of Psychiatry, 158(2), 324.
31. Cohen, D., & McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. Journal of Mind and Behavior, 11, 455-474.
32. Cohen, D., McCubbin, M., Collin, J., & Perodeau, G. (2001). Medications as social phenomena. Health, 5, 441-469.
33. Deniker, P. (1986). Are the anti-psychotic drugs to be withdrawn? In C. Shagass, R. Josiassen, & W. Bridger (Eds.), Biological psychiatry (pp. 19). New York: Elsevier.
34. Diamond, R. (1985). Drugs and the quality of life: The patient’s point of view. Journal of Clinical Psychiatry, 46, 29-35.
35. Drug treatments for schizophrenia. (1999). Effective Health Care, 5(6), 1-12.
36. Durst, R., Teitelbaum, A., Katz, G., & Knobler, H. Y. (1999). Withdrawal from clozapine: The "rebound phenomenon." Israel Journal of Psychiatry and Related Sciences, 36, 122-128.
37. Dziegielewski, S. F. (1998). Psychopharmacology and social work practice: Introduction. Research on Social Work Practice, 8, 371-383.
38. Ekblom, B., Eriksson, K., & Lindstrom, L. H. (1984). Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology, 83, 293-294.
39. Elwood, M. (1998). Critical appraisal of epidemiological studies and clinical trials. New York: Oxford University Press.
40. Fisher, S., & Greenberg, R. P. (1993). How sound is the double-blind design for evaluating psychotropic drugs? Journal of Nervous and Mental Disease, 181, 345-350.
41. Fisher, S., & Greenberg, R. P. (Eds.). (1997). From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley.
42. Fleming, S. T. (2000). Randomized clinical trials. In S. T. Fleming, F. D. Scutchfield, & T. C. Tucker (Eds.), Managerial epidemiology (pp. 97-120). Chicago: Health Administration Press.
43. Fourrier, A., Gasquet, I., Allicar, M. P., Bouhassira, M., Lepine, J. P., & Begaud, B. (2000). Patterns of neuroleptic drug prescription: A national cross-sectional survey of a random sample of French psychiatrists. British Journal of Clinical Psychopharmacology, 49(1), 80-86.
44. Frazier, J. A., Giedd, J. N., Kaysen, D., Albus, K., Hamburger, S., et al. (1996). Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment. American Journal of Psychiatry, 153, 564-566.
45. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 32, 1371-1376.
46. Gelman, S. (1999). Medicating schizophrenia: A history. New Brunswick, NJ: Rutgers University Press.
47. Gerlach, J., & Larsen, E. B. (1999). Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatrica Scandinavica, 395(Suppl.), 113-117.
48. Gilbert, P. L., Harris, M. J., McAdams, L. A., & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Archives of General Psychiatry, 52, 173-188.
49. Gomory, T. (1999). Programs of assertive community treatment (PACT): A critical review. Ethical Human Sciences and Services, 1, 147-163.
50. Goodwin, G. M. (1994). Recurrence of mania after lithium withdrawal: Implications for the use of lithium in the treatment of bipolar affective disorder. British Journal of Psychiatry, 164, 149-152.
51. Gosden, R. (2001). Punishing the patient: How psychiatrists misunderstand and mistreat schizophrenia. Melbourne: Scribe.
52. Gosden, R., & Beder, S. (2001). Pharmaceutical industry agenda setting in mental health policies. Ethical Human Sciences and Services, 3, 147-159.
53. Gur, R. E., Maany, V., Mozley, P. D., Swanson, C., Bilker, W., & Gur, R. C. (1998). Subcortical MRI volumes of neuroleptic-naive and treated patients with schizophrenia. American Journal of Psychiatry, 155, 1711-1717.
54. Halliday, G. M., Pond, S. M., Cartwright, H., McRitchie, D. A., Castagnoli, N., Jr., & Van der Schyf, C. J. (1999). Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyrine analog of haloperidol. Experimental Neurology, 158, 155-163.
55. Harrison, P. J. (1999). The neuropathological effects of antipsychotic drugs. Schizophrenia Research, 40(2), 87-99.
56. Healy, D. (2002, February). Problems with antidepressants. Paper presented at the Institute of Psychiatry, London.
57. Healy, D., & Farquhar, G. (1998). Immediate effects of droperidol. Human Psychopharmacology, 13, 113-120.
58. Hegarty, J., Baldessarini, R. J., Tohen, M., Waternaux, C., & Oepen, G. (1994). One hundred years of schizophrenia: A metaanalysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
59. Hensley, S., & Burton, T. M. (2001, May 8). Mind games: Pfizer, Eli Lilly spar for schizophrenia market. The Wall Street Journal, B4.
60. Hird, S. (2000). Psychotropic medications. In S. G. Austrian, (Eds.), Mental disorders, medications, and clinical social work (pp. 272-290). New York: Columbia University Press.
61. Hogarty, G. E., & Ulrich, R. F. (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research, 32, 243-250.
62. Huston, P., & Moher, D. (1996). Redundancy, disaggregation, and the integrity of medical research. Lancet, 347, 1024-1026.
63. Irwin, P., & Singer, J. (1988). A guide for clinical studies with potential antipsychotic or antidepressant medications. Clinical Research Practices & Drug Regulatory Affairs, 6, 293-411.
64. Chalmers, I. (1990). Underreporting research is scientific misconduct. JAMA, 263, 1405-1408.
65. Choudhry, N. K., Stelfox, H. T., & Detsky, A. S. (2002). Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA, 287, 612-617.
66. Cohen, B. M., Herschel, M., Miller, E., Mayberg, H., & Baldessarini, R. J. (1980). Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology, 19, 663-668.
67. Cohen, D. (1994). Neuroleptic drug treatment of schizophrenia: The state of the confusion. Journal of Mind and Behavior, 15, 139-156.
68. Cohen, D. (1997a). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher & R. G. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 173-228). New York: Wiley.
69. Cohen, D. (1997b). Psychiatrogenics: Introducing chlorpromazine in psychiatry. Review of Existential Psychology and Psychiatry, 23, 206-233.
70. Cohen, D. (2001). Medication-free minors with schizophrenia. American Journal of Psychiatry, 158(2), 324.
71. Cohen, D., & McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. Journal of Mind and Behavior, 11, 455-474.
72. Cohen, D., McCubbin, M., Collin, J., & Perodeau, G. (2001). Medications as social phenomena. Health, 5, 441-469.
73. Deniker, P. (1986). Are the anti-psychotic drugs to be withdrawn? In C. Shagass, R.Josiassen, & W. Bridger (Eds.), Biological psychiatry (pp. 19). New York: Elsevier.
74. Diamond, R. (1985). Drugs and the quality of life: The patient’s point of view. Journal of Clinical Psychiatry, 46, 29-35.
75. Drug treatments for schizophrenia. (1999). Effective Health Care, 5(6), 1-12.
76. Durst, R., Teitelbaum, A., Katz, G., & Knobler, H. Y. (1999). Withdrawal from clozapine: The "rebound phenomenon." Israel Journal of Psychiatry and Related Sciences, 36, 122-128.
77. Dziegielewski, S. F. (1998). Psychopharmacology and social work practice: Introduction. Research on Social Work Practice, 8, 371-383.
78. Ekblom, B., Eriksson, K., & Lindstrom, L. H. (1984). Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology, 83, 293-294.
79. Elwood, M. (1998). Critical appraisal of epidemiological studies and clinical trials. New York: Oxford University Press.
80. Fisher, S., & Greenberg, R. P. (1993). How sound is the double-blind design for evaluating psychotropic drugs? Journal of Nervous and Mental Disease, 181, 345-350.
81. Fisher, S., & Greenberg, R. P. (Eds.). (1997). From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley.
82. Fleming, S. T. (2000). Randomized clinical trials. In S. T. Fleming, F. D. Scutchfield, & T. C. Tucker (Eds.), Managerial epidemiology (pp. 97-120). Chicago: Health Administration Press.
83. Fourrier, A., Gasquet, I., Allicar, M. P., Bouhassira, M., Lepine, J. P., & Begaud, B. (2000). Patterns of neuroleptic drug prescription: A national cross-sectional survey of a random sample ofFrench psychiatrists. British Journal of Clinical Psychopharmacology, 49(1), 80-86.
84. Frazier, J. A., Giedd, J. N., Kaysen, D., Albus, K., Hamburger, S., et al. (1996). Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment. American Journal of Psychiatry, 153, 564-566.
85. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 32, 1371-1376.
86. Gelman, S. (1999). Medicating schizophrenia: A history. New Brunswick, NJ: Rutgers University Press.
87. Gerlach, J., & Larsen, E. B. (1999). Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatrica Scandinavica, 395(Suppl.), 113-117.
88. Gilbert, P. L., Harris, M. J., McAdams, L. A., & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Archives of General Psychiatry, 52, 173-188.
89. Gomory, T. (1999). Programs of assertive community treatment (PACT): A critical review. Ethical Human Sciences and Services, 1, 147-163.
90. Goodwin, G. M. (1994). Recurrence of mania after lithium withdrawal: Implications for the use of lithium in the treatment of bipolar affective disorder. British Journal of Psychiatry, 164, 149-152.
91. Gosden, R. (2001). Punishing the patient: How psychiatrists misunderstand and mistreat schizophrenia. Melbourne: Scribe.
92. Gosden, R., & Beder, S. (2001). Pharmaceutical industry agenda setting in mental health policies. Ethical Human Sciences and Services, 3, 147-159.
93. Gur, R. E., Maany, V., Mozley, P. D., Swanson, C., Bilker, W., & Gur, R. C. (1998). Subcortical MRI volumes of neuroleptic-naive and treated patients with schizophrenia. American Journal ofPsychiatry, 155, 1711-1717.
94. Halliday, G. M., Pond, S. M., Cartwright, H., McRitchie, D. A., Castagnoli, N., Jr., & Van der Schyf, C. J. (1999). Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyrine analog of haloperidol. Experimental Neurology, 158, 155-163.
95. Harrison, P. J. (1999). The neuropathological effects of antipsychotic drugs. Schizophrenia Research, 40(2), 87-99.
96. Healy, D. (2002, February). Problems with antidepressants. Paper presented at the Institute of Psychiatry, London.
97. Healy, D., & Farquhar, G. (1998). Immediate effects of droperidol. Human Psychopharmacology, 13, 113-120.
98. Hegarty, J., Baldessarini, R. J., Tohen, M., Waternaux, C., & Oepen, G. (1994). One hundred years of schizophrenia: A metaanalysis of the outcome literature. American Journal ofPsychiatry, 151, 1409-1416.
99. Hensley, S., & Burton, T. M. (2001, May 8). Mind games: Pfizer, Eli Lilly spar for schizophrenia market. The Wall Street Journal, B4.
100. Hird, S. (2000). Psychotropic medications. In S. G. Austrian, (Eds.), Mental disorders, medications, and clinical social work (pp. 272-290). New York: Columbia University Press.
101. Hogarty, G. E., & Ulrich, R. F. (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research, 32, 243-250.
102. Huston, P., & Moher, D. (1996). Redundancy, disaggregation, and the integrity of medical research. Lancet, 347, 1024-1026.
103. Irwin, P., & Singer, J. (1988). A guide for clinical studies with potential antipsychotic or antidepressant medications. Clinical Research Practices & Drug Regulatory Affairs, 6, 293-411.
104. Jacobs, D. H., & Cohen, D. (1999). What is really known about psychological alterations produced by psychiatric drugs? International Journal of Risk and Safety in Medicine, 12, 37-47.
105. Jauss, M., Schroder, J., Pantel, J., Bachmann, S., Gerdsen, I., & Mundt, C. (1998). Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry, 31(4), 146-148.
106. Jeste, D. V., Lohr, J. B., Eastman, J. H., Rockwell, E., & Caligiuri, M. P. (1999). Adverse neurobiological effects of long-term use of neuroleptics: Human and animal studies. Journal of Psychiatric Research, 32, 201-214.
107. Karagianis, J. L., Phillips, L. C., Hogan, K. P., & LeDrew, K. K. (1999). Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Annals of Pharmacotherapy, 33, 623-630.
108. Keen, E. (1998). Drugs, therapy, and professional power: Problems and pills. Westport, CT: Praeger.
109. Kelly, C., & McCreadie, R. G. (1999). Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry, 156, 1751-1757.
110. Kendrick, T. (1999). The newer, ’atypical’ antipsychotic drugs: Their development and current therapeutic use. British Journal of General Practice, 49, 745-749.
111. Kirk, S. A., & Kutchins, H. (1992). The selling of DSM: The rhetoric of science in psychiatry. Chicago: Aldine.
112. Kornhuber, J., Schultz, A., Wiltfang, J., Meineke, I., Gleiter, C. H., Zochling, R., et al. (1999). Persistence of haloperidol in human brain tissue. American Journal of Psychiatry, 156, 885-890.
113. Koshino, Y. (1999). Algorithm for treatment-refractory schizophrenia. Psychiatry & Clinical Neurosciences, 53(Suppl.), S9-S13.
114. Liberman, R. P., Van Putten, T., Marshall, B. D., Mintz, J., Bowen, L., Kuehnel, T. G. et al. (1994). Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. American Journal of Psychiatry, 151, 756-759.
115. Llorca, P. M., Vaiva, G., & Lancon, C. (2001). Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Canadian JoumalofPsychiatry, 46, 87-88.
116. Lohr, J. B., Caligiuri, M. P., Manley, M. S., & Browning, J. A. (2000). Neuroleptic-induced striatal damage in rats: A study of antioxidant treatment using acceleretromic and immunocytochemical methods. Psychopharmacology, 148, 171-179.
117. Mason, S. E., Bermanzohn, P. C., & Siris, S. G. (1998). Clinical trials and tribulations: Implementation processes in schizophrenia research outcome. Psychiatry: Interpersonal & Biological Processes, 61, 288-301.
118. Modestin, J., Stephan, P. L., Erni, T., & Umari, T. (2000). Prevalence of extrapyramidal symptoms in psychiatric patients and the relationship of clozapine treatment to tardive dyskinesia. Schizophrenia Research, 42, 223-230.
119. Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials. Journal of Nervous and Mental Disease, 189, 288-295.
120. Public Citizen. (2001, July). The other drug war: Big pharma’s 625 Washington lobbyists. Washington, DC: Author.
121. Ramaekers, J. G., Louwerens, J. W., Muntjewerff, N. D., Milius, H., de Bie, A., Rosenzweig, P., et al. (1999). Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpiride) and a classic (haloperidol) antipsychotic. Journal of Clinical Psychopharmacology, 19, 209-221.
122. Ross, C. A., & Pam, A. (Eds.). (1995). Pseudoscience in biological psychiatry: Blaming the body. New York: Wiley.
123. Sands, R. G. (2001). Clinical social work practice in behavioral mental health: A postmodern approach to practice with adults (2nd ed.). Boston: Allyn and Bacon.
124. Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal, 165, 1475-1488.
125. Schatzberg, A. F., Haddad, P., Kaplan, E., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., et al. (1997). Serotonin reuptake inhibitor discon-tinuationsyndrome: Ahypothetical definition. Journal of Clinical Psychiatry, 58(Suppl. 7), 5-10.
126. Selemon, L. D., Lidow, M. S., & Goldman-Rakic, P. S. (1999). Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biological Psychiatry, 46(2), 161-172.
127. Siebert, A. (1999). Brain disease hypothesis of schizophrenia discontinued by all evidence. Ethical Human Sciences and Services, 1, 179-189.
128. Silverstein, K. (1999). Prozac.org: An influential mental health nonprofit finds its "grassroots" watered by pharmaceutical millions. Mother Jones [Electronic version]. Retrieved February 8, 2002 from www.motherjones.com/mother_jones/ND99/nami.html
129. Smith, E. B. (1989). Effect of investigator bias in clinical trials. Archives of Dermatology, 125, 216-218.
130. Spivak, M., & Smart, M. (2000). Tardive dyskinesia from low-dose risperidone. Canadian Journal of Psychiatry, 45, 202.
131. Stanfield, S. C., & Privette, T. (2000). Neuroleptic malignant syndrome associated with olanzapine therapy: A case report. Journal of Emergency Medicine, 19, 355-357.
132. Suppes, T., Baldessarini, R. J, Faedda, G. L., Tondo, L., & Tohen, M. (1993). Discontinuation of maintenance treatment in bipolar disorder: Risks and implications. Harvard Review of Psychiatry, 1(3), 131-144.
133. Thapa, P. B., Meador, K. G., Gideon, P., Fought, R. L., & Ray, W. A. (1994). Effects of antipsychotic drug withdrawal in elderly nursing home residents. Journal of the American Geriatrics Society, 42, 280-286.
134. The tightening grip of big pharma [Editorial]. (2001). The Lancet, 357, 1141.
135. Thornley, B., & Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal, 317, 1181-1184.
136. Timmerman, L. (2002, February 19). FDA headache: Balancing safety and drug approval. The Seattle Times [Electronic version]. Retrieved February 19, 2002 from http://archives.seattletimes.nwsource.com [Keyword: Food and Drug Administration]
137. Tognoni, G. (1999). Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. European Journal of Clinical Pharmacology, 55, 685-690.
138. Tollefson, G. D., Dellva, M. A., Mattler, C. A., Kane, J. M., Wirshing, D. A., & Kinon, B. J. (1999). Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology, 19, 435-443.
139. Tranter, R., & Healy, D. (1998). Neuroleptic discontinuation syndromes. Journal of Psychopharmacology, 12, 401-406.
140. Valenstein, E. S. (1998). Blaming the brain: The truth about drugs and mental health. New York: Free Press.
141. Vergano, D. (2001, May 17). Drug companies send unfavorable research to the nether regions. USA Today, D8.
142. Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999). Evidence of clozapine’s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. American Journal of Psychiatry, 156, 990-999.
143. Wallace, M. (1994). Schizophrenia-A national emergency: Preliminary observations on SANELINE. Acta Psychiatrica Scandinavica, 89(Suppl. 380), 33-35.
144. Whitaker, R. (2001). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge, MA: Perseus.
145. Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry, 159, 469-473.
146. Zumbrunnen, T. L., & Jann, M. W. (1998). Drug interactions with antipsychotic agents: Incidence and therapeutic implications. CNS Drugs, 9, 381-401.